ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2017-4-195-206ssmu-1037Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSХарактеристика дендритных клеток у больных ревматоидным артритом с различным типом медикаментозной терапииCharacteristics of dendritic cells from patients with rheumatoid arthritis and different type of drug therapyКурочкинаЮ. Д.KurochkinaYu. D.

аспирант

лаборатория клеточной иммунотерапии

врач-ревматолог

клиника иммунопатологии

630099, г. Новосибирск, ул. Ядринцевская, 14 

Postgraduate Student, Laboratory of Cellular Immunotherapy, Doctor-rheumatologist, Clinic of Immunopathology

14, Yadrintsevskaya Str., Novosibirsk, 630099

Juli_k@bk.ruТихоноваМ. А.TikhonovaM. A.

канд. биол. наук, ст. науч. сотрудник

лаборатория клеточной иммунотерапии

630099, г. Новосибирск, ул. Ядринцевская, 14 

PhD, Superior Researcher, Laboratory of Cellular Immunotherapy

14, Yadrintsevskaya Str., Novosibirsk, 630099

ТыриноваТ. В.TyrinovaT. V.

канд. мед. наук, науч. сотрудник

лаборатория клеточной иммунотерапии

630099, г. Новосибирск, ул. Ядринцевская, 14 

PhD, Researcher, Laboratory of Cellular Immunotherapy

14, Yadrintsevskaya Str., Novosibirsk, 630099

ЛеплинаО. Ю.LeplinaO. Yu.

д-р мед. наук, вед. науч. сотрудник

лаборатория клеточной иммунотерапии

630099, г. Новосибирск, ул. Ядринцевская, 14 

DM, Leading Researcher, Laboratory of Cellular Immunotherapy

14, Yadrintsevskaya Str., Novosibirsk, 630099

СизиковА. Э.SizikovA. E.

канд. мед. наук, зав. отделением

отделение ревматологии клиники иммунопатологии

630099, г. Новосибирск, ул. Ядринцевская, 14 

PhD, Head of Rheumatology Department, Clinic of Immunopathology

14, Yadrintsevskaya Str., Novosibirsk, 630099

СулутьянА. Э.SulutianA. E.

канд. мед. наук, врач-ревматолог

отделение ревматологии клиники иммунопатологии

630099, г. Новосибирск, ул. Ядринцевская, 14 

PhD, Doctor-rheumatologist of the Rheumatology Department, Clinic of Immunopathology

14, Yadrintsevskaya Str., Novosibirsk, 630099

КоненковаЛ. П.KonenkovaL. P.

врач-ревматолог

отделение ревматологии клиники иммунопатологии

630099, г. Новосибирск, ул. Ядринцевская, 14 

PhD, Doctor-rheumatologist of the Rheumatology Department, Clinic of Immunopathology

14, Yadrintsevskaya Str., Novosibirsk, 630099

ЧумасоваО. А.ChumasovaO. A.

канд. мед. наук, врач-ревматолог

отделение ревматологии клиники иммунопатологии

630099, г. Новосибирск, ул. Ядринцевская, 14 

PhD, Doctor-rheumatologist of the Rheumatology Department, Clinic of Immunopathology

14, Yadrintsevskaya Str., Novosibirsk, 630099

ОстанинА. А.OstaninA. A.

д-р мед. наук, профессор, гл. науч. сотрудник

лаборатория клеточной иммунотерапии

630099, г. Новосибирск, ул. Ядринцевская, 14 

DM, Professor, Main Researcher, Laboratory of Cellular Immunotherapy

14, Yadrintsevskaya Str., Novosibirsk, 630099

ЧерныхЕ. Р.ChernykhE. R.

д-р мед. наук, профессор, член-корреспондент РАН, зав. лабораторией

лаборатория клеточной иммунотерапии

630099, г. Новосибирск, ул. Ядринцевская, 14 

DM, Рrofessor, Corresponding Member of the Russian Academy of Sciences, Head of the Laboratory of Cellular Immunotherapy

14, Yadrintsevskaya Str., Novosibirsk, 630099

Научно-исследовательский институт фундаментальной и клинической иммунологии (НИИФиКИ)РоссияScientific Institution Research Institute of Fundamental and Clinical ImmunologyRussian Federation201702012018164195206Copyright © Курочкина Ю.Д., Тихонова М.А., Тыринова Т.В., Леплина О.Ю., Сизиков А.Э., Сулутьян А.Э., Коненкова Л.П., Чумасова О.А., Останин А.А., Черных Е.Р., 20182018Курочкина Ю.Д., Тихонова М.А., Тыринова Т.В., Леплина О.Ю., Сизиков А.Э., Сулутьян А.Э., Коненкова Л.П., Чумасова О.А., Останин А.А., Черных Е.Р.Kurochkina Y.D., Tikhonova M.A., Tyrinova T.V., Leplina O.Y., Sizikov A.E., Sulutian A.E., Konenkova L.P., Chumasova O.A., Ostanin A.A., Chernykh E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/1037Цель исследования

Цель исследования. Сравнительное исследование фенотипических и функциональных свойств дендритных клеток (ДК) в группах больных ревматоидным артритом (РА), получающих болезнь-модифицирующие препараты, либо биологические препараты и (или) пульс-терапию высокими дозами глюкокортикоидов.

Материал и методы

Материал и методы. В исследование включены 39 пациентов с РА и 20 сопоставимых по возрасту и полу здоровых доноров. Девятнадцать больных на момент обследования получали терапию стандартными болезнь-модифицирующими препаратами (БМП) в виде монотерапии или в комбинации (группа РА1), 20 – биологические препараты либо пульс-терапию глюкокортикоидами (группа РА2). В последнем случае обследование проводилось на 2–7-е сут после последнего введения метилпреднизолона.

Результаты

Результаты. В настоящем исследовании впервые описаны свойства ДК, генерируемых из моноцитов под действием IFN-α (IFN-ДК), при РА. Установлено, что общей особенностью ДК в группах РА1 и РА2 являются признаки незрелости ДК, проявляющиеся усилением экспрессии CD14 и снижением доли зрелых (CD14-CD83+) ДК. Несмотря на различия ДК в группах РА1 и РА2, оба типа клеток сохраняют in vitro чувствительность к действию дексаметазона, обработка которым приводит к значительному угнетению продукции TNF-α и снижению аллостимуляторной активности ДК. Таким образом, IFN-ДК у больных РА, получающих медикаментозную терапию, характеризуются наличием толерогенных свойств, которые наиболее выражены при использовании в программе лечения биологических препаратов или пульс-терапии кортикостероидами. 

Purpose of the study

Purpose of the study. Comparative study of the phenotypic and functional properties of dendritic cells (DC) in groups of patients with rheumatoid arthritis (RA) receiving disease-modifying drugs, or biological drugs and (or) pulse therapy with high doses of glucocorticoids.

Materials and methods

Materials and methods. The study included 39 patients with RA and 20 age-appropriate and semihealthy donors. Nineteen patients were treated with standard disease-modifying drugs (BMP) in the form of monotherapy or in combination (group PA1) at the time of the examination, 20 – biological preparations or pulse-therapy with glucocorticoids (group PA2). In the latter case, the examination was carried out for 2–7 days after the last injection of methylprednisolone.

Results

Results. In this study, the properties of DC generated from monocytes under the action of IFN-α (IFN-DK) for RA are described for the first time. It has been established that the general feature of DC in the PA1 and PA2 groups are signs of immaturity of the DC, manifested by increased CD14 expression and a decrease in the proportion of mature (CD14-CD83 +) DC. Despite the differences in DC in the PA1 and PA2 groups, both cell types retain in vitro sensitivity to dexamethasone, the treatment of which leads to a significant inhibition of TNF-α production and a decrease in allostimulant activity of the DC. Thus, IFN-DK in RA patients receiving medical therapy is characterized by the presence of tolerogenic properties, which are most pronounced when used in a program of treatment of biological agents or pulse therapy with corticosteroids. 

ревматоидный артритдендритные клеткидексаметазонинтерферон альфаrheumatoid arthritisdendritic cellsdexamethasoneinterferon αReferencesTsark E.C., Wang W., Teng Y.C., Arkfeld D., Dodge G.R., Kovats S. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages // J. Immunol. 2002; 169 (11): 6625–6633. DOI: 10.4049/jimmunol.169.11.6625.Tsark E.C., Wang W., Teng Y.C., Arkfeld D., Dodge G.R., Kovats S. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages // J. Immunol. 2002; 169 (11): 6625–6633. DOI: 10.4049/jimmunol.169.11.6625.Wenink M.H., Han W., Toes R.E., Radstake T.R. Dendritic cells and their potential implication in pathology and treatment of rheumatoid arthritis // Handb. Exp. Pharmacol. 2009; 188: 81–98. DOI: 10.1007/978-3-540- 71029-5_4.Wenink M.H., Han W., Toes R.E., Radstake T.R. Dendritic cells and their potential implication in pathology and treatment of rheumatoid arthritis // Handb. Exp. Pharmacol. 2009; 188: 81–98. DOI: 10.1007/978-3-540- 71029-5_4.Khan S., Greenberg J.D., Bhardwaj N. Dendritic cells as targets for therapy in rheumatoid arthritis. Nat. Rev.Rheumatol. 2009; 5 (10): 566–571. DOI: 10.1038/ nrrheum.2009.185.Khan S., Greenberg J.D., Bhardwaj N. Dendritic cells as targets for therapy in rheumatoid arthritis. Nat. Rev.Rheumatol. 2009; 5 (10): 566–571. DOI: 10.1038/ nrrheum.2009.185.Liu J., Cao X. Regulatory dendritic cells in autoimmunity: a comprehensive review // J. Autoimmun. 2015; 63: 1–12. DOI: 10.1016/j.jaut.2015.07.011.Liu J., Cao X. Regulatory dendritic cells in autoimmunity: a comprehensive review // J. Autoimmun. 2015; 63: 1–12. DOI: 10.1016/j.jaut.2015.07.011.Thomas R., MacDonald K.P., Pettit A.R., Cavanagh L.L., Padmanabha J., Zehntner S. Dendritic cells and the pathogenesis of rheumatoid arthritis // J. Leukoc. Biol. 1999; 66 (2): 286–292. PMID: 10449169.Thomas R., MacDonald K.P., Pettit A.R., Cavanagh L.L., Padmanabha J., Zehntner S. Dendritic cells and the pathogenesis of rheumatoid arthritis // J. Leukoc. Biol. 1999; 66 (2): 286–292. PMID: 10449169.Santiago-Schwarz F., Anand P., Liu S., Carsons S.E. Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses // J. Immunol. 2001; 167 (3): 1758–1768. DOI: 10.4049/jimmunol.167.3.1758.Santiago-Schwarz F., Anand P., Liu S., Carsons S.E. Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses // J. Immunol. 2001; 167 (3): 1758–1768. DOI: 10.4049/jimmunol.167.3.1758.Chen K., Wang J.M., Yuan R., Yi X., Li L., Gong W., Yang T., Li L., Su S. Tissue-resident dendritic cells and diseases involving dendritic cell malfunction // Int. Immunopharmacol. 2016; 34: 1–15. DOI: 10.1016/j.intimp.2016.02.007.Chen K., Wang J.M., Yuan R., Yi X., Li L., Gong W., Yang T., Li L., Su S. Tissue-resident dendritic cells and diseases involving dendritic cell malfunction // Int. Immunopharmacol. 2016; 34: 1–15. DOI: 10.1016/j.intimp.2016.02.007.Hilkens C.M.U., Isaacs J.D. Tolerogenic dendritic cells in clinical practice // Open Arthritis Journal. 2010; 3: 8–12. DOI: 10.2174/1876539401003010008.Hilkens C.M.U., Isaacs J.D. Tolerogenic dendritic cells in clinical practice // Open Arthritis Journal. 2010; 3: 8–12. DOI: 10.2174/1876539401003010008.Torres-Aguilar H., Aguilar-Ruiz S.R., Gonzalez-Perez G., Munguia R., Bajaсa S., Meraz-Rios M.A., Sanchez-Torres C. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells // J. Immunol. 2010; 184 (4): 1765–1775. DOI: 10.4049/jimmunol.0902133.Torres-Aguilar H., Aguilar-Ruiz S.R., Gonzalez-Perez G., Munguia R., Bajaсa S., Meraz-Rios M.A., Sanchez-Torres C. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells // J. Immunol. 2010; 184 (4): 1765–1775. DOI: 10.4049/jimmunol.0902133.Yu X., Wang C., Luo J, Zhao X., Wang L., Li X. Combination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo // Clin. Dev. Immunol. 2013; 2013: 238035. DOI: 10.1155/2013/238035.Yu X., Wang C., Luo J, Zhao X., Wang L., Li X. Combination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo // Clin. Dev. Immunol. 2013; 2013: 238035. DOI: 10.1155/2013/238035.Piemonti L., Monti P., Allavena P., Sironi M., Soldini L., Leone B.E., Socci C.,Di Carlo V.. Glucocorticoids affect human dendritic cell differentiation and maturation // J. Immunol. 1999; 162 (11): 6473–6481.Piemonti L., Monti P., Allavena P., Sironi M., Soldini L., Leone B.E., Socci C.,Di Carlo V.. Glucocorticoids affect human dendritic cell differentiation and maturation // J. Immunol. 1999; 162 (11): 6473–6481.Xia C.Q., Peng R., Beato F., Clare-Salzler M.J. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity // Scand. J. Immunol. 2005; 62 (1): 45–54. DOI: 10.1111/j.1365- 3083.2005.01640.x.Xia C.Q., Peng R., Beato F., Clare-Salzler M.J. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity // Scand. J. Immunol. 2005; 62 (1): 45–54. DOI: 10.1111/j.1365- 3083.2005.01640.x.León B., Ardavín C. Monocyte-derived dendritic cells in innate and adaptive immunity // Immunol. Cell. Biol. 2008; 86 (4): 320–324. DOI: 10.1038/icb.2008.León B., Ardavín C. Monocyte-derived dendritic cells in innate and adaptive immunity // Immunol. Cell. Biol. 2008; 86 (4): 320–324. DOI: 10.1038/icb.2008.Epub 2008 Mar 25. 14. Gessani S., Conti L., Del Cornò M., Belardelli F. Type I interferons as regulators of human antigen presenting cell functions // Toxins (Basel). 2014; 6 (6): 1696–1723. DOI: 10.3390/toxins6061696.Epub 2008 Mar 25. 14. Gessani S., Conti L., Del Cornò M., Belardelli F. Type I interferons as regulators of human antigen presenting cell functions // Toxins (Basel). 2014; 6 (6): 1696–1723. DOI: 10.3390/toxins6061696.Runnblom L., Eloranta M.L. The interferon signature in autoimmune diseases // Curr. Opin. Rheumatol. 2013; 25 ( 2): 248–253. DOI: 10.1097/BOR.0b013e32835c7e32.Runnblom L., Eloranta M.L. The interferon signature in autoimmune diseases // Curr. Opin. Rheumatol. 2013; 25 ( 2): 248–253. DOI: 10.1097/BOR.0b013e32835c7e32.Rodriguez-Carrio J., de Paz B., Lуpez P., Prado C., Alperi-Lуpez M., Ballina-Garcнa F.J., Suarez A. IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients // PLoS One. 2014; 9 (1): e86069. DOI: 10.1371/journal.pone.0086069.Rodriguez-Carrio J., de Paz B., Lуpez P., Prado C., Alperi-Lуpez M., Ballina-Garcнa F.J., Suarez A. IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients // PLoS One. 2014; 9 (1): e86069. DOI: 10.1371/journal.pone.0086069.Miossec P., Naviliat A., Duput-dAngeac A., Sany J., Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis // Arthr. Rheum. 1999; 33: 1180–1187. DOI: 10.1002/art.1780330819.Miossec P., Naviliat A., Duput-dAngeac A., Sany J., Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis // Arthr. Rheum. 1999; 33: 1180–1187. DOI: 10.1002/art.1780330819.Chen E., Keystone E.C., Fish E.N. Restricted cytokine expression in rheumatoid arthritis // Arthritis Rheum. 1993; 36 (7): 901–910. PMID:8318038.Chen E., Keystone E.C., Fish E.N. Restricted cytokine expression in rheumatoid arthritis // Arthritis Rheum. 1993; 36 (7): 901–910. PMID:8318038.Prevoo M.L., van ‘t Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts.Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis // Arthritis Rheum. 1995;38 (1):44–8. DOI: http://dx.doi. org/10.1002/art.1780380107.Prevoo M.L., van ‘t Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts.Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis // Arthritis Rheum. 1995;38 (1):44–8. DOI: http://dx.doi. org/10.1002/art.1780380107.Курочкина Ю.Д., Леплина О.Ю., Тихонова М.А., Тыринова Т.В., Баторов Е.В., Сизиков А.Э., Оста- нин А.А., Черных Е.Р. Влияние дексаметазона на интерферон-α- индуцированную дифференцировку моноцитов в дендритные клетки // Медицинская им- мунология. 2016; 18 (4): 347–356. DOI: 10.15789/1563- 0625-2016-4-347-356. Kurochkina Y.D., Leplina O.Y., Tikhonova M.A., Tyrinova T.V., Batorov E.V., Sizikov A.E., Ostanin A.A., Chernykh E.R. Effect of dexamethasone on interferon-α-induced differentiation of monocytes to dendritic cells // Medical Immunology (Russia). 2016; 18 (4): 347–356 (in Russian). DOI: 10.15789/1563-0625-2016-4-347-356.Курочкина Ю.Д., Леплина О.Ю., Тихонова М.А., Тыринова Т.В., Баторов Е.В., Сизиков А.Э., Оста- нин А.А., Черных Е.Р. Влияние дексаметазона на интерферон-α- индуцированную дифференцировку моноцитов в дендритные клетки // Медицинская им- мунология. 2016; 18 (4): 347–356. DOI: 10.15789/1563- 0625-2016-4-347-356. Kurochkina Y.D., Leplina O.Y., Tikhonova M.A., Tyrinova T.V., Batorov E.V., Sizikov A.E., Ostanin A.A., Chernykh E.R. Effect of dexamethasone on interferon-α-induced differentiation of monocytes to dendritic cells // Medical Immunology (Russia). 2016; 18 (4): 347–356 (in Russian). DOI: 10.15789/1563-0625-2016-4-347-356.Rutella S., De Cristofaro R., Ferraccioli G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases // Hum. Immunol. 2009; 70: 360–373. PMID: 19405176.Rutella S., De Cristofaro R., Ferraccioli G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases // Hum. Immunol. 2009; 70: 360–373. PMID: 19405176.Broder A., Chan J.J., Putterman C. Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases // Clin. Immunol. 2013; 146 (3): 197–206. DOI: 10.1016/j.clim.2012.12.002.Broder A., Chan J.J., Putterman C. Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases // Clin. Immunol. 2013; 146 (3): 197–206. DOI: 10.1016/j.clim.2012.12.002.Wenink M.H., Han W., Toes R.E., Radstake T.R. Dendritic cells and their potential implication in pathology and treatment of rheumatoid arthritis // Handb. Exp Pharmacol. 2009; 188: 81–98. DOI: 10.1007/978-3-540-71029-5_4.Wenink M.H., Han W., Toes R.E., Radstake T.R. Dendritic cells and their potential implication in pathology and treatment of rheumatoid arthritis // Handb. Exp Pharmacol. 2009; 188: 81–98. DOI: 10.1007/978-3-540-71029-5_4.García-González P.A., Schinnerling K., Sepúlveda-Gutiérrez A., Maggi J., Hoyos L., Morales R.A., Mehdi A.M., Nel H.J., Soto L., Pesce B., Molina M.C., Cuchacovich M., Larrondo M.L., Neira Ó., Catalán D.F., Hilkens C.M., Thomas R., Verdugo R.A., Aguillón J.C. Treatment with dexamethasone and monophosphoryl lipid a removes disease-associated transcriptional signatures in monocyte-derived dendritic cells from rheumatoid arthritis patients and confers tolerogenic features // Front. Immunol. 2016; 7: 458. eCollection 2016.García-González P.A., Schinnerling K., Sepúlveda-Gutiérrez A., Maggi J., Hoyos L., Morales R.A., Mehdi A.M., Nel H.J., Soto L., Pesce B., Molina M.C., Cuchacovich M., Larrondo M.L., Neira Ó., Catalán D.F., Hilkens C.M., Thomas R., Verdugo R.A., Aguillón J.C. Treatment with dexamethasone and monophosphoryl lipid a removes disease-associated transcriptional signatures in monocyte-derived dendritic cells from rheumatoid arthritis patients and confers tolerogenic features // Front. Immunol. 2016; 7: 458. eCollection 2016.Balanescu A., Radu E., Nat R., Regalia T., Bojinca V., Ionescu R., Balanescu S., Savu C., Predeteanu D. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients // Int. J. Clin. Pharmacol. Res. 2005; 25 (1): 9–18. PMID: 15864873.Balanescu A., Radu E., Nat R., Regalia T., Bojinca V., Ionescu R., Balanescu S., Savu C., Predeteanu D. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients // Int. J. Clin. Pharmacol. Res. 2005; 25 (1): 9–18. PMID: 15864873.Wehner R., Bitterlich A., Meyer N., Kloß A., Schäkel K., Bachmann M., Schmitz M. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells // Int. J. Cancer. 2013; 132 (6): 1351–1359. DOI: 10.1002/ijc.27786.Wehner R., Bitterlich A., Meyer N., Kloß A., Schäkel K., Bachmann M., Schmitz M. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells // Int. J. Cancer. 2013; 132 (6): 1351–1359. DOI: 10.1002/ijc.27786.Raker V.K., Domogalla M.P., Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man // Front. Immunol. 2015; 6: 569. DOI: 10.3389/fimmu.2015.00569.Raker V.K., Domogalla M.P., Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man // Front. Immunol. 2015; 6: 569. DOI: 10.3389/fimmu.2015.00569.Chamorro S. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program // J. Immunol. 2009; 183 (5): 2984–2994. DOI: 10.4049/jimmunol.0801155.Chamorro S. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program // J. Immunol. 2009; 183 (5): 2984–2994. DOI: 10.4049/jimmunol.0801155.Radstake T.R., Nabbe K.C., Wenink M.H., Roelofs M.F., Oosterlaar A., van Lieshout A.W., Barrera P., van Lent P.L., van den Berg W.B. Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of FcRII expression, which has clear functional consequences // Ann. Rheum. Dis. 2005; 64: 1737–1743. DOI: 10.1136/ard.2004.034405.Radstake T.R., Nabbe K.C., Wenink M.H., Roelofs M.F., Oosterlaar A., van Lieshout A.W., Barrera P., van Lent P.L., van den Berg W.B. Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of FcRII expression, which has clear functional consequences // Ann. Rheum. Dis. 2005; 64: 1737–1743. DOI: 10.1136/ard.2004.034405.Harry R.A., Anderson A.E., Isaacs J.D., Hilkens C.M. Generation and characterization of therapeutic tolerogenic dendritic cells for rheumatoid arthritis // Ann. Rheum. Dis. 2010; 69 (11): 2042–2050. DOI: 10.1136/ ard.2009.126383.Harry R.A., Anderson A.E., Isaacs J.D., Hilkens C.M. Generation and characterization of therapeutic tolerogenic dendritic cells for rheumatoid arthritis // Ann. Rheum. Dis. 2010; 69 (11): 2042–2050. DOI: 10.1136/ ard.2009.126383.Estrada-Capetillo L., Hernandez-Castro B., MonsivaisUrenda A., Alvarez-Quiroga C., Layseca-Espinosa E., Abud-Mendoza C., Baranda L., Urzainqui А., Sanchez-Madrid F., Gonzalez-Amaro R. Induction of Th17 lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with rheumatoid arthritis and systemic lupus erythematosus // Clin. Dev. Immunol. 2013; 2013, Article ID 584303, 9. DOI: 10.1155/2013/584303.Estrada-Capetillo L., Hernandez-Castro B., MonsivaisUrenda A., Alvarez-Quiroga C., Layseca-Espinosa E., Abud-Mendoza C., Baranda L., Urzainqui А., Sanchez-Madrid F., Gonzalez-Amaro R. Induction of Th17 lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with rheumatoid arthritis and systemic lupus erythematosus // Clin. Dev. Immunol. 2013; 2013, Article ID 584303, 9. DOI: 10.1155/2013/584303.Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., Leenen P.J., Liu Y.J., MacPherson G., Randolph G.J., Scherberich J., Schmitz J., Shortman K., Sozzani S., Strobl H., Zembala M., Austyn J.M., Lutz M.B. Nomenclature of monocytes and dendritic cells in blood // Blood. 2010;116: e74–e80. DOI: 10.1182/blood2010-02-258558.Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., Leenen P.J., Liu Y.J., MacPherson G., Randolph G.J., Scherberich J., Schmitz J., Shortman K., Sozzani S., Strobl H., Zembala M., Austyn J.M., Lutz M.B. Nomenclature of monocytes and dendritic cells in blood // Blood. 2010;116: e74–e80. DOI: 10.1182/blood2010-02-258558.Sprangers S., de Vries T.J., Everts V. Monocyte heterogeneity: consequences for monocyte-derived immune cells // Journal of Immunology Research. 2016; Article ID 1475435, 10.Sprangers S., de Vries T.J., Everts V. Monocyte heterogeneity: consequences for monocyte-derived immune cells // Journal of Immunology Research. 2016; Article ID 1475435, 10.Balboa L., Romero M.M., Laborde E. et al. Impaired dendritic cell differentiation of CD16-positive monocytes in tuberculosis: role of p38 MAPK // European Journal of Immunology. 2013; 43 (2); 335–347. DOI: 10.1002/eji.201242557.Balboa L., Romero M.M., Laborde E. et al. Impaired dendritic cell differentiation of CD16-positive monocytes in tuberculosis: role of p38 MAPK // European Journal of Immunology. 2013; 43 (2); 335–347. DOI: 10.1002/eji.201242557.Rossol M., Kraus S., Pierer M., Baerwald C., Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population // Arthritis Rheum. 2012; 64: 671–677. DOI: 10.1002/art.33418.Rossol M., Kraus S., Pierer M., Baerwald C., Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population // Arthritis Rheum. 2012; 64: 671–677. DOI: 10.1002/art.33418.Radwan W.M. , Khalifa R.A., Esaily H.A., Lashin N.A. CD14++CD16+ monocyte subset expansion in rheumatoid arthritis patients: Relation to disease activity and interleukin-17 // The Egyptian Rheumatologist. 2016; 38 (3): 161–169. http://dx.doi.org/10.1016/j.ejr.2015.12.002.Radwan W.M. , Khalifa R.A., Esaily H.A., Lashin N.A. CD14++CD16+ monocyte subset expansion in rheumatoid arthritis patients: Relation to disease activity and interleukin-17 // The Egyptian Rheumatologist. 2016; 38 (3): 161–169. http://dx.doi.org/10.1016/j.ejr.2015.12.002.Cooper D.L., Martin S.G., Robinson J.I., Mackie S.L., Charles C.J., Nam J., Consortium Y., Isaacs J.D., Emery P., Morgan A.W. FcgammaRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy // PLoS ONE. 2012;7:e28918. DOI: 10.1371/journal.pone.0028918.Cooper D.L., Martin S.G., Robinson J.I., Mackie S.L., Charles C.J., Nam J., Consortium Y., Isaacs J.D., Emery P., Morgan A.W. FcgammaRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy // PLoS ONE. 2012;7:e28918. DOI: 10.1371/journal.pone.0028918.Liu B., Dhanda A., Hirani S., Williams E.L., Sen H.N., Martinez Estrada F., Ling D., Thompson I., Casady M., Li Z., Si H., Tucker W., Wei L., Jawad S., Sura A., Dailey J., Hannes S., Chen P., Chien J.L., Gordon S., Lee R.W., Nussenblatt R.B. CD14++CD16+ Monocytes are enriched by glucocorticoid treatment and are functionally attenuated in driving effector T-cell responses // J. Immunol. 2015; 194 (11): 5150–5160. DOI: 10.4049/jimmunol. 1402409.Liu B., Dhanda A., Hirani S., Williams E.L., Sen H.N., Martinez Estrada F., Ling D., Thompson I., Casady M., Li Z., Si H., Tucker W., Wei L., Jawad S., Sura A., Dailey J., Hannes S., Chen P., Chien J.L., Gordon S., Lee R.W., Nussenblatt R.B. CD14++CD16+ Monocytes are enriched by glucocorticoid treatment and are functionally attenuated in driving effector T-cell responses // J. Immunol. 2015; 194 (11): 5150–5160. DOI: 10.4049/jimmunol. 1402409.Chara L., Sánchez-Atrio A., Pérez A., Cuende E., Albarrán F., Turrión A., Chevarria J., Sánchez M.A., Monserrat J., de la Hera A., Prieto A., Sanz I., Diaz D., Alvarez-Mon M. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis // Arthritis Res. Ther. 2012; 14 (4): R175. DOI: 10.1186/ar3928.Chara L., Sánchez-Atrio A., Pérez A., Cuende E., Albarrán F., Turrión A., Chevarria J., Sánchez M.A., Monserrat J., de la Hera A., Prieto A., Sanz I., Diaz D., Alvarez-Mon M. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis // Arthritis Res. Ther. 2012; 14 (4): R175. DOI: 10.1186/ar3928.Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking // Science. 1998; 282: 480–483.Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking // Science. 1998; 282: 480–483.Farkas A., Kemény L. Interferon-α in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology // Br. J. Dermatol. 2011; 165 (2): 247-54. DOI: 10.1111/j.1365-2133.2011.10301.x.Farkas A., Kemény L. Interferon-α in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology // Br. J. Dermatol. 2011; 165 (2): 247-54. DOI: 10.1111/j.1365-2133.2011.10301.x.

The authors declare that there are no conflicts of interest present.